Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early‐onset fetal growth restriction
Authors:
- R. N. SpencerRSR. N. Spencer
- A. L. DavidADA. L. David
- EVERREST ConsortiumECEVERREST Consortium
- 9 March 2016
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 47 (4) , 484-491
Abstract
Objective: To evaluate the ethical and social acceptability of a proposed clinical trial using maternal uterine artery vascular endothelial growth factor (VEGF) gene therapy to treat severe early‐onset fetal growth restriction (FGR) in pregnant women.Methods: We conducted a literature review on the ethics and legality of experimental treatments in pregnant women, in particular advanced therapeutics. Issues that were identified from the literature helped develop interview guides for semistructured, qualitative interviews, carried out in four European countries, with 34 key stakeholders (disability groups, professional bodies and patient support groups) and 24 women/couples who had experienced a pregnancy affected by severe early‐onset FGR.Results: The literature review identified two main questions: ‘is it ethical to give a pregnant woman a potentially risky treatment from which she does not benefit directly?’ and ‘is it ethical to treat a condition of the unborn child, who may then be born with a serious disability when, without treatment, they would have died?’. The review concluded that there were no ethical or legal objections to the intervention, or to a trial of this intervention. Overall, respondents viewed the proposed trial in positive terms. Women were generally interested in participating in clinical trials that conferred a potential benefit to their unborn child. The risk of disability of the premature child was a concern, but not considered a major stumbling block for maternal VEGF gene therapy.Conclusions: This study did not identify any fundamental or insurmountable objections to a trial of maternal gene therapy for severe early‐onset FGR. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Local Over-Expression of VEGF-DΔNΔC in the Uterine Arteries of Pregnant Sheep Results in Long-Term Changes in Uterine Artery Contractility and AngiogenesisPLOS ONE, 2014
- Treatment of poor placentation and the prevention of associated adverse outcomes – what does the future hold?Prenatal Diagnosis, 2014
- Uteroplacental Adenovirus Vascular Endothelial Growth Factor Gene Therapy Increases Fetal Growth Velocity in Growth-Restricted Sheep PregnanciesHuman Gene Therapy, 2014
- Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A165 in the uterine arteries of pregnant sheepGene Therapy, 2011
- An Ethically Justified Framework for Clinical Investigation to Benefit Pregnant and Fetal PatientsThe American Journal of Bioethics, 2011
- Obstetric management of intrauterine growth restrictionBest Practice & Research Clinical Obstetrics & Gynaecology, 2009
- Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheepGene Therapy, 2008
- Bioethics and Women2006
- Qualitative Research in Health Care2006
- Ethical Issues in Maternal-Fetal Medicine2002